CTIC - Superstudie für Krebsmedikament - Aktie +50 % - 500 Beiträge pro Seite

[TOP@Man]

what a day

http://www.cticseattle.com/default.htm

das schaut gut aus ..............



T O P

[TOP@Man]

[TOP@Man]

vorbörslich in den USA
263.968 gehandelte Aktien

bid 2,80
ask 2,83

wait and see

guten Handel


T O P

[TOP@Man]

Pre-Market
Last: $2.80 Pre-Market
Best Bid: N/A Pre-Market
High: $2.95
Pre-Market
Volume: 273,868 Pre-Market
Best Ask: N/A Pre-Market
Low: $2.76

[DMKE]

wie gewonnen so zerronnen ...

[TOP@Man]

29.09.2005


Pre-Market
Time (ET) Pre-Market
Price Pre-Market
Share Volume
08.15 $ 2.78 1000
08.15 $ 2.78 400
08.15 $ 2.77 1200
08.15 $ 2.75 1000
08.14 $ 2.75 2000
08.14 $ 2.76 1000
08.13 $ 2.78 1500
08.13 $ 2.76 2000
08.12 $ 2.78 100
08.11 $ 2.74 4000
08.11 $ 2.74 900
08.11 $ 2.72 100
08.08 $ 2.68 2000
08.07 $ 2.65 2300
08.05 $ 2.60 1280
08.05 $ 2.60 100
08.04 $ 2.65 297
08.04 $ 2.65 703
08.04 $ 2.63 1000

[TOP@Man]

gute halbe Stunde vor der Glocke

Market Trade Reporting Thursday September 29

Pre-Market
Last: $2.87 Pre-Market
Best Bid: N/A Pre-Market
High: $2.89
Pre-Market
Volume: 155,055 Pre-Market
Best Ask: N/A Pre-Market
Low: $2.60


Pre-Market
Time (ET) Pre-Market
Price

[TOP@Man]

knappe halbe Stunde vor der Glocke


$2.85 Pre-Market
Best Bid: N/A Pre-Market
High: $2.88
Pre-Market
Volume: 22,300 Pre-Market
Best Ask: N/A Pre-Market
Low: $2.83

[TOP@Man]

NEWS +++



Seite: 1 > .. 31 .. 60
07.10.2005 23:54:00 (PR NEWSWIRE)

Cell Therapeutics unter den Spitzenunternehmen bei Deloitte`s "Washington State Technology Fast 50"


SEATTLE, October 7 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) gehört zu den führenden Unternehmen bei der alljährlich aufgestellten Rangliste des Deloitte & Touche "Washington State Technology Fast 50." Bei diesem Award-Programm werden Technologie-Unternehmen innerhalb des Staates Washington nach ihrem Umsatzwachstum über einen Zeitraum von fünf Jahren klassifiziert (2000 - 2004). CTI erreichte mit einem Umsatzwachstum von 5.867 Prozent über 5 Jahre den zweiten Platz, Seattle Genetics, Inc. führt mit einer Steigerung von 6.669 Prozent.

Anzeige:
Schiffsfonds mit Bestnote 2005: progn. Gesamtauszahlung von 220% - nahezu steuerfrei!

"Wir sind sehr erfreut, dass wir in die Fast 50` von Deloitte aufgenommen wurden", so Jim Bianco, Präsident und CEO von CTI. "Wir sahen uns in den letzten Jahren mit zahlreichen Herausforderungen konfrontiert, haben es aber geschafft, in diesem Zeitraum ein konstantes Umsatzwachstum aufrechzuerhalten. Unsere Bemühungen, uns dieses Jahr verstärkt auf das Unternehmen zu konzentrieren und Umstruktrurierungsmassnahmen durchzuführen, werden sich auf das Wachstum im Jahr 2005 niederschlagen, und wir hoffen, uns auch in der Zukunft wieder für die Liste der Fast 50` qualifizieren zu können."

Unternehmensprofil Cell Therapeutics, Inc.

CTI ist ein biopharmazeutisches Unternehmen mit Firmensitz in Seattle, das sich der Entwicklung eines ganzheitlichen Portfolios an onkologischen Produkten verschrieben hat, die die Behandlungsmöglichkeiten von Krebs verbessern sollen. Weitere Informationen finden Sie unter www.cticseattle.com.

[TOP@Man]

+++ N E W S +++

Patent Broadens Global Market Potential for XYOTAX

SEATTLE, Oct. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced that it has received notification from the Japanese Patent Office that patent coverage extending to XYOTAX(TM) (paclitaxel poliglumex) is allowable in Japan. CTI has an exclusive license to this Japanese patent property. The patent, when issued, will provide patent protection for XYOTAX in Japan until 2018. In addition to this licensed patent property in Japan, CTI has licensed issued patents in the United States and allowed coverage in Europe that encompass XYOTAX.

"This event helps to solidify our development efforts in Japan in coordination with our partner, Chugai," stated James A. Bianco, M.D., President and CEO of CTI. "This patent will complement CTI`s existing licensed patent portfolio, extending XYOTAX`s exclusivity to the Japanese market. This is an important step toward securing the global market potential of XYOTAX as we move forward with the approval process."

Currently, CTI plans to submit a New Drug Application (NDA) and seek approval for XYOTAX as first-line monotherapy for women with advanced non- small cell lung cancer (NSCLC) who have poor performance status (PS2). The filing in Europe will also seek use as monotherapy in first-line PS2 patients with NSCLC, but is not expected to be limited to women; however, additional input on the statistical interpretation of non-inferiority will be needed from the scientific committee of the European Medicines Agency (EMEA) prior to submitting a Marketing Authorization Application (MAA).

About XYOTAX

XYOTAX (paclitaxel poliglumex) is a pharmaceutical that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially trapped in the tumor blood vessels allowing significantly more of the dose of chemotherapy to localize in the tumor.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

[TOP@Man]

N E W S

-------------------

Cell Therapeutics, Inc. Announces $82 Million in Convertible Senior Notes Offering



Company Concurrently Agrees to Retire $38.4 Million of Old Debt Through Equity
Exchange
SEATTLE, Nov. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today entered into an agreement to issue $82 million of 6.75% convertible senior notes ("Notes") due in 2010 only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Notes Agreement").

The Notes will bear interest at a rate of 6.75% per annum and will be convertible for shares of CTI common stock at the rate of 378.78 shares per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $2.63 per share, which is equal to 110% of the closing bid price on October 31, 2005. The Notes will rank pari passu in right of payment with all existing and future senior indebtedness of CTI, and will rank senior in right of payment to CTI`s currently outstanding convertible notes. Holders of the Notes would also have the right to cause CTI to redeem up to 30% of the aggregate principal amount of the Notes (or approximately $24.6 million) on a pro rata basis on April 30, 2006, and any such redemption would exclude any accrued and unpaid interest. The Notes Agreement is expected to close by November 4, 2005, subject to closing conditions, including the condition that the prospective investors have not withdrawn their commitment to purchase the Notes. CTI cannot provide any assurance regarding the amount of Notes to be issued, if any, until the Notes Agreement is closed.

CTI also announced today that it has entered into a Conversion and Placement Agreement ("CAP Agreement") with two qualified institutional buyers who are existing holders (the "CAP Holders") of an aggregate amount of approximately $38.38 million of its outstanding 5.75% Convertible Senior Subordinated Notes due June 15, 2008 ("5.75% Notes") and 4% Convertible Senior Subordinated Notes due July 1, 2010 ("4% Notes"). Pursuant to the terms of the CAP Agreement, the CAP Holders have agreed to exercise their right to convert their 5.75% Notes and 4% Notes into approximately 3.3 million shares of CTI common stock. In consideration for the CAP Holders exercising their conversion rights, CTI has agreed to issue to the CAP Holders approximately 9.9 million shares of its common stock. The CAP Holders have agreed to be investors in the above described Notes Agreement. The closing of the CAP Agreement is expected to coincide with, and is conditioned upon, the closing of the Notes Agreement.

These securities have not been registered under the Securities Act of 1933, as amended, or any state securities laws. The Notes, the common stock issuable upon conversion of the Notes and the common stock CTI has agreed to issue to the CAP Holders in consideration for the exercising of their conversion rights under the 4% Notes and 5.75% Notes may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any applicable state laws.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

For more information, refer to the following table detailing certain transaction data.

Certain Transaction Data
Retirement of $38.4 million of existing convertible debt

Annual Aggregate Maturity Conversion Shares to New
coupon amount of date price per be issued issued
old debt share upon restricted
being conversion shares
retired

5.75% $18.53
million 2008 $10.00 1,853,000
4.00% $19.85
million 2010 $13.50 1,470,371
Total $38.38
million 3,323,371 9,877,932

Issuance of $82.0 million of new convertible debt

Annual Aggregate amount Maturity Conversion Shares issuable
coupon of new debt date price per upon conversion
share
6.75% $82.0 million (1) 2010 $2.63 31,178,707

(1) $24.6 million of this debt is subject to mandatory redemption by the Company on April 30, 2006 at the option of the holders. Any such mandatory redemption will exclude accrued and unpaid interest.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the above described transaction will not close as a result of the failure to meet closing conditions, investors may breach or withdraw their commitment, and until closed there is no assurance that it will close or what the total amount may be, and other risk factors listed or described from time to time in the Company`s filings with the Securities and Exchange Commission including, without limitation, the Company`s most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward- looking statements whether as a result of new information, future events, or otherwise.

SOURCE Cell Therapeutics, Inc.
-0- 11/01/2005
/CONTACT: investors, Leah Grant, [phone], or fax,
[phone], or [e-mail], or
www.cticseattle.com/investors.htm, or media, Susan Callahan, [phone],
or fax, [phone], or [e-mail], or
www.cticseattle.com/media.htm, both of Cell Therapeutics, Inc./
/Web site: http://www.cticseattle.com/
(CTIC)

CO: Cell Therapeutics, Inc.
ST: Washington
IN: BIO MTC
SU:

JB-EB
-- SFTU110 --
3290 11/01/200507:43 ESThttp://www.prnewswire.com

[TOP@Man]

wait and see.............


T O P

[TOP@Man]

+++N E W S +++
----------------------

CTIC
Cell Therapeutics, Inc. NASDAQ-NM




Back to Headlines | Previous Story



Addition of Pixantrone to Rituxan(R) Therapy Significantly Prolongs Time to Disease Progression and Improves the Overall Response Rate Compared to Rituxan Alone in Relapsed or Refractory Indolent Lymphoma



Randomized Controlled Trial Meets Primary and Secondary Endpoints
NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- At a presentation at the CIBC World Markets 16th Annual Healthcare Conference, Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) presented results from a randomized controlled study of Rituxan versus Rituxan plus pixantrone in 38 relapsed or refractory patients who had previously failed up to five prior treatments for indolent non-Hodgkin`s lymphoma (NHL). The study achieved its primary objective of prolonging the time before a patient`s lymphoma progressed (time to disease progression, or TTP). Patients receiving the combination of Rituxan and pixantrone had an 87 percent overall improvement in TTP compared to Rituxan alone. The median TTP estimate for the pixantrone/Rituxan recipients was 13.2 months compared to 8.1 months for Rituxan alone (hazard ratio 0.13, log rank p <0.001). The one- and two-year progression-free survival estimates were 66 percent and 44 percent for the pixantrone/Rituxan recipients compared to zero percent for the Rituxan patients for both measurement intervals (p <0.001 and 0.003, respectively). The study also met its secondary endpoint demonstrating a significant improvement in major objective responses (>/= 50 percent shrinkage in tumor size). Seventy-five percent of patients treated with the pixantrone/Rituxan combination achieved a major response, with 35 percent achieving a complete response. This compares to 33 percent major response in patients who received Rituxan monotherapy, including 11 percent achieving a complete response (p = 0.02). Side effects on pixantrone were generally mild (grade 1 or 2) with the exception of severe (grade 4) treatment-related neutropenia, which was seen in two patients. The median cumulative dose of pixantrone administered was 1014 mg/m2; no cases of treatment-related grade 3 or 4 cardiac toxicity were reported.

"Obviously we are very pleased and excited by these results, which demonstrate a significant advantage of adding pixantrone to the standard of care, Rituxan, in treating indolent non-Hodgkin`s lymphoma," noted Jack W. Singer, M.D. Chief Medical Officer at CTI. "Despite the small sample size, the high degree of statistical significance underscores the notable activity of pixantrone in indolent NHL."

About the Phase III trial

The multi-center randomized trial, also known as PIX302, evaluated the addition of pixantrone (90 mg/m2 given on days 1 and 8 every 21 days) to standard Rituxan therapy (375 mg/m2 given on days 1, 8, 22, and 29) to Rituxan therapy alone among patients with relapsed or refractory indolent NHL. The trial was designed, pursuant to a SPA (Special Protocol Assessment) with the FDA, to enroll a total of 728 patients in order to detect a 30 percent improvement in TTP between treatment arms, the primary endpoint of the study. Overall response rate was a secondary endpoint of the trial. Patients with histologically confirmed CD20 positive NHL who had failed one or more prior treatments were included in the trial. Exclusion criteria consisted of patients who were shown to be resistant to Rituxan or who had prior stem cell or bone marrow transplants. The study was stratified for known risk factors that may impact response and duration of response including IPI classification, number of prior regimens (1-2 versus >2), and prior anti-CD20 regimen. Patients were followed for 24 months with disease assessments made at 3-month intervals following their last day of drug therapy.

The study was closed in 2004 due to difficulty in meeting the initial enrollment target. A total of 38 patients were evaluable for response; 20 patients (median age 67 years) were randomized to the pixantrone/Rituxan arm with 18 patients (median age 59 years) on the Rituxan arm. The pixantrone-Rituxan combination produced a complete response (CR) in seven patients (35 percent), with 8 patients (40 percent) experiencing a partial response (PR) and four patients (20 percent) with stable disease (SD). Rituxan monotherapy produced a CR in 2 patients (11 percent), PR in 4 patients (22 percent) with 6 patients having SD (33 percent). This corresponds to a major objective response rate of 75 percent in the combination therapy arm compared to 33 percent in the Rituxan group (p=0.021). The combination of Rituxan and pixantrone was well tolerated with the only severe (grade 4) toxicity reported being neutropenia in two patients. Other toxicities were generally mild to moderate and consistent with the known safety profile for Rituxan monotherapy, except for mild (grade 1-2) cardiac side effects, fatigue, anorexia, and alopecia, which were seen only on the combination treatment arm.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors, and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin`s lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company`s filings with the Securities and Exchange Commission including, without limitation, the Company`s most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

SOURCE Cell Therapeutics, Inc.
-0- 11/09/2005
/CONTACT: Leah Grant, [phone], or fax, [phone], or
[e-mail], or www.cticseattle.com/investors.htm, or press, Susan
Callahan, [phone], or fax, [phone], or [e-mail],
or www.cticseattle.com/media.htm, both of Cell Therapeutics, Inc./
/Web site: http://www.cticseattle.com/
(CTIC)

CO: Cell Therapeutics, Inc.
ST: Washington
IN: BIO MTC HEA
SU: TRI

EB
-- SFW052 --
0310 11/09/200508:30 ESThttp://www.prnewswire.com

[TOP@Man]

+++ N E W S+++
---------------------


Cell Therapeutics, Inc. to Report Third Quarter Financial Results on November 14



SEATTLE, Nov. 10 /PRNewswire-FirstCall/ -- On Monday, November 14, 2005, at 9:00 a.m. Eastern/6:00 a.m. Pacific time, members of Cell Therapeutics, Inc.`s (CTI) (Nasdaq: CTIC; MTAX) management team will host a quarterly conference call to discuss the Company`s 2005 third quarter achievements and financial results.

According to the Form NT 10-Q filed by CTI on November 9, CTI`s 10Q quarterly report was delayed to allow its independent auditor, Stonefield Josephson, Inc., which was appointed on October 14, 2005, to complete their review of the Company`s unaudited financial statements. CTI anticipates filing the 10-Q for the period ended September 30, 2005, along with its unaudited financials statements, on November 14, within the allowed extension period. All of the Company`s other required periodic reports have been filed in a timely manner and the Company does not anticipate any significant change in results of operations from the corresponding period for the last fiscal year.


Third Quarter Financial Conference Call
Monday, November 149:00 a.m. Eastern/6:00 a.m. Pacific
1-888-385-9734 (US Participants)
1-773-756-4818 (International)
Passcode: CTIC

Live audio webcast at
www.cticseattle.com
Will be archived for post listening
approximately 2 hours after call ends

Call-back numbers for post listening:
1-800-839-3139
1-203-369-3126
Passcode: CTIC


SOURCE Cell Therapeutics, Inc.
-0- 11/10/2005
/CONTACT: investors, Leah Grant, [phone], or fax,
[phone], or [e-mail], or media, Susan Callahan,
[phone], or fax, [phone], or [e-mail], both of
Cell Therapeutics, Inc./
/Web site: http://www.cticseattle.com/media.htm" target="_blank" rel="nofollow ugc noopener">http://www.cticseattle.com/media.htm /
/Web site: http://www.cticseattle.com/investors.htm" target="_blank" rel="nofollow ugc noopener">http://www.cticseattle.com/investors.htm /
/Web site: http://www.cticseattle.com/
(CTIC)

CO: Cell Therapeutics, Inc.
ST: Washington
IN: BIO MTC HEA
SU: CCA

TX-CD
-- SFTH076 --
2141 11/10/200516:35 ESThttp://www.prnewswire.com

[TOP@Man]

+++ NEWS +++ Quartalszahlen

----------------------------------

CTIC
Cell Therapeutics, Inc. NASDAQ-NM




Back to Headlines | Previous Story



Cell Therapeutics, Inc. Reports Third Quarter 2005 Financial Results



Refocused Operations Leads to Significant Cost Reductions While Maintaining

XYOTAX(TM) Registration and Pixantrone Development Timelines

SEATTLE, Nov. 14 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) reported financial results for the third quarter ended September 30, 2005. Total revenues for the quarter were $1.3 million, including TRISENOX(R) net sales of $1.2 million, which were recorded prior to the closing of the divestiture to Cephalon on July 18. CTI reported a net loss for the quarter of $8.5 million ($0.13 per share), after giving effect to a gain of $30.5 million on TRISENOX divestiture, compared to a net loss of $34.9 million ($0.62 per share) for the same period in 2004. The Company ended the quarter with approximately $41 million in cash and cash equivalents, securities available-for-sale, and interest receivable.

"We are pleased to see the positive impact our refocusing efforts are having on both cost reductions and the efficiency of our operations in our Seattle and Bresso facilities. The Company is focused on our regulatory filings for XYOTAX and advancing pixantrone to the phase III interim analysis, two important milestones for CTI in 2006," stated James A. Bianco, M.D., President and CEO of CTI. "With a reduced burn rate, achievable development goals, and a strengthened balance sheet, this has been a very productive quarter."

Recent Highlights

* Completed the divestiture of TRISENOX to Cephalon for approximately
$68 million in cash, subject to a working capital adjustment, or
approximately $28 million after repayment of the amount owed to
PharmaBio Development, Inc., plus up to an additional $100 million in
potential future sales and regulatory milestones
* Completed an $82 million convertible senior notes offering and retired
$38.4 million of outstanding 5.75% and 4% convertible senior
subordinated notes through an equity exchange
* Appointed Stonefield Josephson, Inc. as independent registered public
accounting firm
* Appointed John Bauer, Former Nintendo of America, Inc. Executive Vice
President of Finance, as new board member and Chair of the Company`s
Audit Committee and appointed Phil Nudelman as Chairman of the Board
* Announced XYOTAX patent allowance in Japan, which will provide
exclusivity until 2018

About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of XYOTAX and pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX and pixantrone in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective or be approved for treatment of non-small cell lung cancer, the potential failure of pixantrone to prove safe and effective for treatment of relapsed, aggressive non-Hodgkin`s lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX and pixantrone, and the risk factors listed or described from time to time in the Company`s filings with the Securities and Exchange Commission including, without limitation, the Company`s most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Cell Therapeutics, Inc.

[DMKE]

blicke hier nicht mehr so richtig durch ...
kann das mal jemand kurz ins deutsche zusammen fassen ?
lohnt sich hier ein einstig oder droht eher noch weiterer verlust ?

[TOP@Man]

aktuell geht es wohl eher downhill .........


http://www.cticseattle.com/investors_financial.htm

Das neue Filing.........

CTIC scheint wie viele Biotechunternehmen mit den selben Problem zu kämpfen - entweder sie gehen Pleite oder sie machen die Super/Wahnsinnsentdeckung und zischen ab.

CTIC ist und bleibt ein RISIKOINVESTMENT

wait and see

so long


T O P

[TOP@Man]

+++N E W S +++

A Form S-3 regarding Cell Therapeutics has been filed with the United States Securities and Exchange Commission.

To view this filing, please click here

http://www.cticseattle.com/investors_financial.htm

Sehr risikoreiches INVESTMENT !!!

so long



T O P

[TOP@Man]

+++ N E W S +++ Krebsmedikament -XYOTAX geht in die klinische Testphase !!!
-------------------------------------------------------
Pivotal Trial to Evaluate Comparative Effectiveness of XYOTAX(TM) to Taxol(R) in Women With Advanced Lung Cancer



New Biologically-Enhanced Chemotherapy May Improve Survival in Women
SEATTLE, Dec. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced plans to initiate a clinical trial in women of XYOTAX (paclitaxel poliglumex) versus paclitaxel chemotherapy for the treatment of PS2 (poor performance status) patients with chemotherapy-naive advanced stage non-small cell lung cancer (NSCLC). The trial, known as PIONEER 1, is the first approval trial for lung cancer exclusively targeting women and is expected to enroll 600 patients over the next 12 to 14 months.

"Gaining a better understanding of the biological role of estrogen in the development and progression of lung cancer has become increasingly important, especially with the growing number of women, including non-smokers, being diagnosed often at younger age than men and with different outcomes than men," said Kathy Albain, M.D., Professor of Medicine, Hematology/Oncology and Director, Thoracic Oncology and Breast Clinical Research, Loyola University Health System, and chair of the PIONEER 1 clinical trial steering committee. "Clinical trials that focus on and exploit new data on the biology of lung cancer in women are long overdue. Outcomes will be instrumental in developing tailored therapies, possibly based on gender but even more so, on the molecular biology of the disease. The exploratory data from the initial XYOTAX studies are provocative and validate the design of the PIONEER 1 prospective study."

Data presented at Chemotherapy Foundation Symposium XXIII

This news comes on the heels of a presentation at Chemotherapy Foundation Symposium XXIII in New York City early last month in which new data were presented that may support the scientific rationale of an enhanced survival benefit of women with NSCLC treated with XYOTAX versus standard chemotherapy.

In his presentation, Suresh Ramalingam, M.D., Assistant Professor of Medicine, University of Pittsburgh Cancer Institute noted that the estrogen receptor-mediated pathway plays an important role in NSCLC biology in both men and women. Presenting preliminary data, Ramalingam reported that exposure of lung cancer cells to estrogen increases the gene expression of cathepsin B, a critical enzyme that metabolizes XYOTAX, releasing active paclitaxel within the tumor cell.

"These data suggest that patients with normal estrogen levels may benefit due to the favorable effect of estrogen on XYOTAX metabolism," noted Dr. Ramalingam.

Mark A. Socinski, M.D., Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center at the University of North Carolina Chapel Hill, presented clinical data from a pooled analysis of CTI`s STELLAR 3 and 4 trials. In the 198 women treated on those trials, superior survival was observed in those who received XYOTAX (p=0.03). The most notable impact was among women less than 55 years old and presumably pre-menopausal who were treated with XYOTAX compared to standard chemotherapy (median survival 10.0 vs. 5.3 months, hazard ratio=0.51, log rank p=0.038). While a survival trend (p=0.134) was observed in women 55 years of age and older (post-menopausal), the greater benefit observed among younger women is supportive of a positive impact of estrogen in XYOTAX patients. Further support for this was observed in the STELLAR 3 trial, where blood estrogen levels were retrospectively analyzed. Women with higher estrogen levels, regardless of age, who were treated with XYOTAX in combination with carboplatin had a significant improvement in overall survival compared to women treated with paclitaxel in combination with carboplatin (median survival 10.2 months vs. 5.5 months, hazard ratio=0.54, log rank p=0.039).

"These data are exciting and provide a strong scientific link between estrogen and the effectiveness of XYOTAX, a biologically-enhanced chemotherapy agent, in treating women with lung cancer," stated Dr. Socinski. "These findings open the door to a new avenue of clinical research for gender-specific therapy, not only in lung cancer but in a number of cancers that are known to express the estrogen receptor."

"These presentations highlight how an effect of estrogen on XYOTAX metabolism by tumors may lead to enhanced efficacy in women with lung cancer. It is important to note that XYOTAX was similar in efficacy to standard agents in men but has notable safety and convenience advantages over existing therapies in men and women, particularly when used as a single agent," noted Jack W. Singer, M.D., Chief Medical Officer at CTI.

Gender Differences in Lung Cancer

Several studies have indicated that compared to men, women who smoke are more likely to develop lung cancer at a younger age and at lower levels of exposure to cigarette smoke. Non-smoking women are at higher risk for developing lung cancer than non-smoking men. Research to date has focused on the influence of pharmacogenetic differences between men and women and on the role of estrogen to explain these findings. Estrogen enhances the effects of carcinogens in the environment and in smoke, possibly leading to a higher risk for NSCLC and once it occurs, appears to enhance its development.

Since women have higher levels of estrogen than men, and younger women have higher levels of estrogen than older women, this may in part be responsible for their higher risk for NSCLC. Developing therapies that are favorably influenced by estrogen may provide a gender-targeted therapeutic approach to the treatment of NSCLC.

PIONEER 1 Clinical Trial Protocol

The PIONEER 1 clinical trial is expected to begin patient recruitment in December 2005 in the United States, Eastern Europe, and Latin America with enrollment of 600 PS2 chemotherapy-naïve women with advanced stage NSCLC. Each study arm of approximately 300 patients will be randomized to receive either XYOTAX 175mg/m2 or paclitaxel 175mg/m2 once every three weeks. The primary endpoint is superior overall survival with several secondary endpoints including disease control, response rate in patients with measurable disease, time to disease progression, and disease-related symptoms.

About XYOTAX

XYOTAX (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive potentially sparing normal tissue`s exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Based on preclinical studies, it appears that XYOTAX is preferentially trapped in the tumor blood vessels allowing significantly more of the dose of chemotherapy to localize in the tumor. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer over non-biologically enhanced chemotherapeutic agents.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of XYOTAX include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective or be approved for use in non-small cell lung cancer, risks that the effect of estrogen seen in preclinical studies do not result in a gender effect or improvement in survival of women with non-small cell lung cancer, risks related to the initiation, accrual, and results of the PIONEER 1 trial, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX, and the risk factors listed or described from time to time in the Company`s filings with the Securities and Exchange Commission including, without limitation, the Company`s most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise. Taxol(R) is a registered trademark of Bristol-Myers Squibb Co.

SOURCE Cell Therapeutics, Inc.
-0- 12/06/2005
/CONTACT: Investors, Leah Grant, [phone], or fax,
[phone], or [e-mail], or media, Susan Callahan,
[phone], or fax, [phone], or [e-mail], both of
Cell Therapeutics, Inc./
/Web site: http://www.cticseattle.com /
(CTIC)

[TOP@Man]

+++ N E W S +++
----------------------


neue Filings

http://www.cticseattle.com/investors_financial.htm

vom 17.12.2005 nachbörslich

so long

T O P

[TOP@Man]

+++ N E W S +++
----------------------

[http://www.cticseattle.com/investors_financial.htm

filing vom 21.12.2005 - nachbörslich


Frohe Weihnachten



T O P

[Freddy9]

Bin seit ca. 2 Monaten investiert!
Hier tut sich aber überhaupt nichts !!

schöne Weihnachten
Freddy

[TOP@Man]

+++ N E W S +++



http://www.cticseattle.com/investors_financial.htm

Freddy9 hat leider recht - hier geht seit Monaten NIX oder wenig bzw der Kurs pendelt um die 1,80 € - 2,00 €.

Hier können nur gute NEWS helfen

so long

T O P

[DMKE]

wenn gehts denn hier endlich mal wieder aufwärts ... ?

[whyso]

[posting]19.886.053 von DMKE am 26.01.06 09:46:13[/posting]"wenn gehts denn hier endlich mal wieder aufwärts"



http://www.shortsqueeze.com/index.php?symbol=ctic

http://biz.yahoo.com/ap/060208/cell_therapeutics_xyotax.html…

ab heute, schätze ich, der obige Meldung sei Dank...

Danke für den Tipp MIKE!
Whyso

[DMKE]

so kanns gerne täglich weiter gehen ...

[whyso]

Next week...kommt der heiße Tanz Phase mit CTIC...

[asics01]

kannst du das begründen???

[whyso]

[posting]20.148.632 von asics01 am 11.02.06 08:04:35[/posting]Try this...

Cell Therapeutics, Inc. to Present at BIO CEO & Investor Conference
Thursday February 9, 7:00 am ET

SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX: CTIC) management will present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference next week.
The conference will be held February 14-15, 2006, at the Waldorf-Astoria Hotel in New York City. CTI will present on Wednesday, February 15 at 1:00 p.m. (ET). The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.cticseattle.com.

http://biz.yahoo.com/prnews/060209/sfth038.html?.v=38

Man hat einiges ans "Stoff" im Hause CTIC den man dort bis nächsten Mittwoch den Gesamtmarkt mitteilen darf & wird

Schönen Sonntag noch,
Whyso

[lotte123]

Was kommt heute raus?

[cyberhai]

Survival Benefit Linked to Estrogen in Women Treated With XYOTAX(TM)
Wednesday February 15, 1:30 pm ET
Third Clinical Trial in First-Line Lung Cancer to Demonstrate Superior Survival in Pre-Menopausal Women

NEW YORK, Feb. 15 /PRNewswire-FirstCall/ -- In a presentation at the BIO CEO & Investor conference today, James A. Bianco, M.D., President and CEO of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) presented updated results of a phase II study of XYOTAX in combination with carboplatin among 35 women and 39 men with advanced non-small cell lung cancer (NSCLC). Unlike the STELLAR 3 and 4 trials, where only patients with poor performance status (PS2) were enrolled, there was no restriction on performance status in the phase II trial, known as PGT202. The study was analyzed for overall survival by gender and by estrogen levels to confirm the observation of enhanced efficacy in the presence of estrogen seen in the STELLAR first-line trials. Estimated one-year survival of women receiving XYOTAX is 36 percent compared to only 16 percent of their male counterparts. Consistent with the results seen in the STELLAR 3 trial (XYOTAX/carboplatin), the 12 women with normal estrogen levels (>/=30 pg/ml) survived longer than the 22 women with post-menopausal, low estrogen levels. The estimated median survival for women with low estrogen levels was 128 days (4.2 months) while the median survival among women with normal estrogen levels was 218 days (7.2 months). At the time of last contact, nine of 12 women (75 percent) with normal estrogen levels were alive compared to nine of 22 women (41 percent) with low estrogen levels.

"This phase II study supports what we observed and reported in our prior first-line study of XYOTAX and carboplatin (STELLAR 3) and substantially strengthens the likelihood that the beneficial effect of estrogen on XYOTAX efficacy is valid," stated Bianco. "This gives us a high degree of confidence that we are on the right path by investing in the PIONEER gender-specific study and broadens the potential applicability to all first-line patients, not just PS2 patients."

In a composite analysis of two prior randomized trials (STELLAR 3 and 4), in 198 women with advanced NSCLC who were PS2, patients randomized to receive XYOTAX had a statistically significant improvement in overall survival compared to women treated with comparator agents (hazard ratio 0.70, log rank p=0.03) with one-year survival estimates of 40% vs. 25% (p=0.01). Results among men were similar to the comparator agents. The most common side effects were neuropathy and myelosuppression. Survival significantly correlated with pre-menopausal age and pre-menopausal estrogen levels, where available, consistent with preclinical findings showing that estrogen enhances the biodistribution and release of paclitaxel from the polyglutamate polymer in tumor-bearing tissues, such as the lungs, allowing potentially greater tumor exposure to chemotherapy than can be achieved with standard chemotherapy agents.

[whyso]

[posting]20.217.804 von lotte123 am 15.02.06 15:01:45[/posting]Auf deiner Frage hin:


Steigende Kurse anscheint...

[lotte123]

Schaut euch die Umsätze an. Und das bei steigenden Kursen. Das waren wohl gute Nachrichten.

[whyso]

[posting]20.225.343 von lotte123 am 15.02.06 21:01:21[/posting]und das beste ist die Aufträge an der Markler "sammeln sich noch"

[Corgar]

LOS ANGELES, Feb 21 (Reuters) - Cell Therapeutics Inc. (CTIC.O: Quote, Profile, Research), whose experimental lung cancer drug Xyotax failed in two key clinical trials, still sees promise for the drug and expects to file for U.S. regulatory approval in the fourth quarter of this year, the company`s chief executive said on Tuesday.

While Cell Therapeutics failed to show that Xyotax was superior to standard chemotherapy, the company did find a survival benefit in women taking the drug and has launched a separate trial to test its effectiveness.

CEO James Bianco said at the Reuters Biotechnology Summit in Los Angeles that the company will begin submitting Xyotax data to the U.S. Food and Drug Administration in the fourth quarter of this year and hopes to have a decision from the agency by the second quarter of next year, based on the previous studies and interim results from the latest trial focused on women.

"This will be a good test case, if you will, to see how the FDA looks at the data, even though it is retrospective," Bianco said.

The CEO said the company expects to meet with high-level FDA officials in the second quarter of this year to finalize the filing strategy.

Under the best-case scenario, Cell Therapeutics would be able to launch Xyotax in the fourth quarter of 2007, he said.

"The bar is still pretty high in oncology. Non-inferiority to chemotherapy is not what moves the field forward. They are looking for the next big advance in therapy," Bianco said.

But despite recent advances in targeted therapies for cancer, traditional chemotherapy drugs are likely to be around for years to come, he noted.

"From a strategic standpoint, if chemo will be around for next 15 years, why not change the profile and make it safer?" Bianco said.

He said economic studies have shown that Xyotax would save $47,000 per patient per year of survival because it would limit the need for drugs that treat side effects of chemotherapy as well as additional hospitalizations.

If the company has to wait until the latest trial is complete, the regulatory filing would happen in 2008, Bianco said.

Xyotax links the chemotherapy drug paclitaxel to a substance that binds to tumors, with the goal of reducing damage to healthy cells as well as side effects like nausea and hair loss.

The drug is believed to work better in women because enzymes regulated by the hormone estrogen break down the protein binding, enhancing effectiveness of the treatment.

"The data in women deserves its day in front of the FDA," Bianco said.

He said a few multinational pharmaceutical companies have been particularly interested in the drug`s gender-specific effect and the company hopes to sign up a commercial partner.

In order to do that, Cell Therapeutics would like to regain rights to the drug in Japan and other Asian countries that are now held by Chugai Pharmaceutical Co. Ltd. (4519.T: Quote, Profile, Research).

Such an announcement is likely "within the next few weeks," Bianco said.

Shares of Cell Therapeutics fell 1.5 percent to close at $1.94 on Nasdaq on Tuesday, down some 33 percent since last September.

(Additional reporting by Julie Steenhuysen)

[Buddah]

Vorbörslich im Plus!
könnte schön "rebounden"!

Gruss B.

[genom]

Förtschi hat sie empfohlen

[lotte123]

Wie muss man die Zahlen sehen? Ich denke, hier kann es nur in Richtung Norden gehen.